https://www.selleckchem.com/products/gdc-0077.html
This study aimed to compare the rates of major cardiovascular adverse events in sodium-glucose cotransporter-2 inhibitors (SGLT2I) and dipeptidyl peptidase-4 inhibitors (DPP4I) users in a Chinese population. SGLT2I and DPP4I are increasingly prescribed for type 2 diabetes mellitus patients. However, few population-based studies are comparing their effects on incident heart failure or myocardial infarction. This was a population-based retrospective cohort study using the electronic health record database in Hong Kong, including type 2 d
Like
Comment
Share
